Nicotine Dependence
Conditions
Brief summary
Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes for NRT in subgroups of smokers. The investigators evaluated the efficacy and safety of sublingual nicotine tablets (SNT) for smoking cessation and the association of catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial among Chinese smokers.
Detailed description
All subjects provided written informed consent after a full explanation of the protocol design.
Interventions
DRUGsublingual nicotine
The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
Sponsors
Bronx VA Medical Center
National Institute on Drug Dependence, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Subjects motivated to stop smoking and Han Chinese * aged 20-70 years who lived in the Haidian District of Beijing * smoke ≥10 cigarettes/day * have smoked for ≥3 years * carbon monoxide (CO) level ≥10 p.p.m. in exhaled air
Exclusion criteria
* a history of Diagnostic and Statistical Manual of Mental Disorders-fourth Edition (DSM-IV) psychiatric disorder * alcohol abuse and other drug abuse * with pathological changes in the floor of their mouth * cardiovascular disease * taking psychotropic medications * using other forms of tobacco or any other NRT products during the last 6 months * pregnant or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the exhaled carbon monoxide (CO) level during the 12-week study | The first was 1 day before quit day (baseline), followed by visits after 1, 2, 4, 6 and 8 weeks at the end of treatment (EOT), with a final follow-up visit at 12 weeks. |
Outcome results
None listed